

PK14105

Chemical Properties


CAS No. : 107257-28-3

Formula: C₂₁H₂₀FN₃O₃

Molecular Weight: 381.4

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	PK14105 has been evaluated biologically as a potential radioligand for positron emission tomography (PET) studies targeting peripheral benzodiazepine binding sites (PBBS) receptors. When administered to rats with unilaterally lesioned striata, PK14105 was observed to quickly cross the blood-brain barrier, displaying significant radioactivity retention in the lesioned striatum, in contrast to the unlesioned striatum or cerebellar vermis. Additionally, PK14105 has the capability to inhibit receptor ligands, calcium channel ligands, and co-transporters in all salivary glands.
Targets(IC50)	Others

Solubility Information

Solubility	DMSO: 30 mg/mL (78.66 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6219 mL	13.1096 mL	26.2192 mL
5 mM	0.5244 mL	2.6219 mL	5.2438 mL
10 mM	0.2622 mL	1.311 mL	2.6219 mL
50 mM	0.0524 mL	0.2622 mL	0.5244 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Pascali C et al. The radiosynthesis of [18F]PK 14105 as an alternative radioligand for peripheral type benzodiazepine binding sites. Int J Rad Appl Instrum A. 1990;41(5):477-82.

Franklin C. Wong et al. Affinity Labeling of Membrane Receptors Using Tissue-Penetrating Radiations. Biomed Res Int. 2013, 503095.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481